Canagliflozin vs Ipilimumab

Canagliflozin vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Canagliflozin and Ipilimumab.

Mechanism of Action

Canagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Canagliflozin — 10.6 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Canagliflozin — C24H25FO5S.

Molecular Weight: Canagliflozin — 444.5170 g/mol.

Type: Canagliflozin — Small molecule; Ipilimumab — Antibody.